October 9, 2014 News by Patricia Silva, PhD New Long-lasting Multiple Sclerosis Drug Will Come At a Steep Price Now more than ever, groundbreaking, new therapies for chronic diseases and infections come with high price tags. Earlier in the year, Gilead Sciences’ drugĀ Sovaldi for Hepatitis C, as well as Vertex’s Kalydeco for Cystic Fibrosis, both raised eyebrows over their cost. Now, a new MS therapy is doing the…
October 8, 2014 News by Patricia Silva, PhD NICE Releases New Guidance on Multiple Sclerosis Care The British National Institute for Health and Care Excellence (NICE) updated their guidelines on the provision of health care for multiple sclerosis (MS) patients in the United Kingdom, which number approximately 100,000 people. The institute recommends now that every patient who is suspected to suffer from the…
October 8, 2014 News by Patricia Inacio, PhD Multiple Sclerosis Risk, Protective Factors Explored in New Research Researchers recently uncovered some curious new insights into environmental factors that may rise or lower the risk of developing Multiple Sclerosis. A new study entitled āEnvironmental exposures and the risk of multiple sclerosis investigated in a Norwegian caseācontrol studyā published in October issue of…
October 7, 2014 News by Patricia Silva, PhD Oklahoma Medical Research Foundation Receives Multiple Sclerosis Innovation Grant A scientist from the Oklahoma Medical Research Foundation (OMRF) is the recipient of 1 of only 5 Multiple Sclerosis Innovation grants from German biopharmaceutical company EMD Serono. Manu Nair, the foundation’s Vice President of Technology Ventures, said that this funding from a new collaborative relationship is a crucial step towards…
October 6, 2014 News by Charles Moore Australian Secondary Progressive MS Clinical Trial Tests New Microparticle Therapy New Zealand and Australia-based Innate Immunotherapeutics Limited, a biotechnology company with offices in Sydney and Auckland, has designed and manufactured a unique immunomodulator microparticle pharmaceutical technology. This technology can be used to induce the human immune system designed to fight certain cancers and infections, or modulate certain immune…
October 6, 2014 News by Patricia Inacio, PhD Researchers Find Link Between Multiple Sclerosis & IBD A new study entitled āIntestinal Barrier Dysfunction Develops at the Onset of Experimental Autoimmune Encephalomyelitis, and Can Be Induced by Adoptive Transfer of Auto-Reactive T Cellsā published in September issue of PloS One, reports that disruption of intestinal homeostasis supports Experimental Autoimmune Encephalomyelitis, the prototypic…
October 3, 2014 News by Patricia Inacio, PhD 159 New Multiple Sclerosis Genetic Variations Discovered By Researchers Approximately 110 multiple genetic variationsĀ were previously identified by genome-wide association studies (GWAS) to be associated with Multiple Sclerosis (MS). Now, that number has increased, with more than 159 genetic variants identified, thanks to new research presented by Philip De Jager, M.D., of Brigham and Womenās Hospital, Harvard Medical…
October 3, 2014 News by Patricia Silva, PhD National MS Society Pledges $19 Million Dollars to Fund 54 New Studies 54 new multiple sclerosis (MS)Ā research and development initiatives are set to receive substantial funding in order to accelerate new therapies. The National Multiple Sclerosis Society (NMSS) announced that it has pledged $19 million to fund these new MS studies as part of their mission to better manage…
October 2, 2014 News by Charles Moore QuĆ©bec Government Covers Lemtrada Second-line Treatment For Relapsing-remitting Multiple Sclerosis Genzyme, a Sanofi company, has announced that the Canadian province of QuĆ©bec’s Institut national d’excellence en santĆ© et services sociaux (INESSS) has recommended that the company’s multiple sclerosis (MS) drug Lemtrada (alemtuzumab) 12 mg be included on the provincial drug formulary under “MĆ©dicament d’exception” as a second-line treatment for…
October 2, 2014 News by Patricia Inacio, PhD Multiple Sclerosis Patients Could Benefit From Placenta-based Cell Therapy Recent research reveals that placenta-based cell therapy is both safe and effective for treating both Relapsing-Remitting and progressive forms of MS. A new study entitled āHuman Placenta-Derived Cells (PDA-001) for the Treatment of Adults With Multiple Sclerosis: A Randomized, Placebo-Controlled, Multiple-Dose Studyā and published in August…
October 1, 2014 News by Patricia Inacio, PhD Why MS Patients Should Know What Glatiramer Acetate Therapy Is A new study, entitled āThe Effect of Glatiramer Acetate Therapy on Functional Properties of B Cells From Patients With Relapsing-Remitting Multiple Sclerosisā published online inĀ JAMA Neurology,Ā reports the effect of Glatiramer acetate therapy on B cells in relapsing-remitting multiple sclerosis (MS) patients. This first-of-its-kind study could…
October 1, 2014 News by Patricia Silva, PhD Glialogix Drug for Progressive MS Funded by National Multiple Sclerosis Society San Francisco Bay Area-based Glialogix, Inc., a biopharmaceutical company that specializes in developing novel treatments for multiple sclerosis (MS), announced yesterday that they have closed aĀ Sponsored Research Agreement with Fast Forward, a non-profit organizationĀ that aims to accelerate MS treatment development.Ā Glialogix will receive funding for one of their…